Immunic’s (IMUX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Immunic (NASDAQ:IMUX) in a research report released on Tuesday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

A number of other research analysts have also commented on IMUX. William Blair assumed coverage on shares of Immunic in a research note on Tuesday, March 25th. They set an “outperform” rating on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Immunic in a research note on Thursday, April 10th. Finally, StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Immunic currently has a consensus rating of “Buy” and a consensus price target of $13.20.

Immunic Stock Up 7.6 %

Shares of IMUX opened at $0.99 on Tuesday. Immunic has a 52-week low of $0.83 and a 52-week high of $2.11. The firm has a market capitalization of $89.07 million, a PE ratio of -0.80 and a beta of 1.91. The firm has a 50-day moving average price of $1.08 and a 200 day moving average price of $1.15.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Focus Partners Wealth boosted its stake in shares of Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after acquiring an additional 23,610 shares in the last quarter. 683 Capital Management LLC lifted its holdings in shares of Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares during the last quarter. Millennium Management LLC boosted its position in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC increased its stake in Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its stake in Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.